Novavax, Inc Equity-NMS: NVAX

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$7.09
Open :	$7.08
Today's high :	$8.15
Today's low :	$6.73
52W low :	$5.61
52W high :	$25.66
1Y :	-63%
5Y :	243.19%
EPS(TTM): :	-6.82
Shares O/S :	94.4 M
Market cap :	725.02 M

What is the share price of Novavax, Inc today?

Novavax, Inc (NVAX) share price as of October 4, 2023, is $7.68. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Novavax, Inc?

Yes, Indian Investors can invest in the Novavax, Inc (NVAX) Share by opening an international trading account with Angel One.

How can I purchase Novavax, Inc shares in India?

Purchasing Novavax, Inc (NVAX) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Novavax, Inc (NVAX) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Novavax, Inc?

Yes, you can purchase fractional shares of Novavax, Inc (NVAX) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Novavax, Inc?

The market capitalization of Novavax, Inc on October 4, 2023, is $725.02 M.

In which sector Novavax, Inc belongs?

Novavax, Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Novavax, Inc stocks?

In order to invest in Novavax, Inc (NVAX) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.